Aceragen, Inc

Rare orphan disease company focused on restoring a better life for patients living with rare disease. #Farberdisease

[Aceragen, Inc @aceragen]

The REPRIEVE Phase 2 clinical trial is currently enrolling individuals with #CysticFibrosis who are experiencing an acute pulmonary exacerbation. For more information visit:
https://t.co/nuQGt8qJON
#cysticfibrosisawareness #cysticfibrosisresearch #cfresearch

[Aceragen, Inc @aceragen]

Today Aceragen celebrated #RareDiseaseDay by hearing from patient advocate, @ellabalasa1. Ella shared her journey with #cysticfibrosis, antibiotic resistant infections, and the importance of patient collaboration in clinical research. Thank you, Ella, for sharing your story!

[Aceragen, Inc @aceragen]

Join Aceragen at the WORLDSymposium™ live poster session on Saturday, February 25th from 3:00 – 4:00 PM EST presented by Nils Confer our VP of Medical Affairs.
#RareDiseases #WORLDSymposium #FarberDisease

[Aceragen, Inc @aceragen]

Did you know that 72% of rare diseases are related to genetics? Increasing access to genetic testing is important for timely diagnosis and treatment. Aceragen is supporting access to no-cost genetic testing for Farber disease and ASAH1. Learn more: https://t.co/RYBjrfIFzR

[Aceragen, Inc @aceragen]

Acute worsening of #cysticfibrosis respiratory symptoms, pulmonary exacerbations (PEx), often requires #antibiotic treatment, increasing concern for #antimicrobialresistance. Our clinical trial pursues treatment for acute PEx in #CF patients. Learn more: https://t.co/6z9J6eI2iP

[Aceragen, Inc @aceragen]

Mark your calendars, it’s almost #RareDiseaseDay! On February 28, Aceragen will be joining the global movement to raise awareness and generate change for the 300 million people living with a rare disease, their families, and caregivers. Learn more at https://t.co/x6F0olzArh

[Aceragen, Inc @aceragen]

It's an exciting day for Aceragen! We have completed our transition to a public company and are in a stronger position as we continue toward our goal of transforming the care of people living with rare pulmonary and rheumatic diseases. https://t.co/KuvJopJJ6b

[Aceragen, Inc @aceragen]

We are excited to launch the new online resource, https://t.co/4VyROaqR1f. This site was developed for patients, caregivers, families, and healthcare professionals interested in learning more about Farber disease and available genetic testing. #farberdisease #ASAH1 #raredisease

[Aceragen, Inc @aceragen]

November is #NationalFamilyCaregiversMonth. We want to honor #familycaregivers and raise awareness of the issues they face. Responsibilities can be significant when caring for a family member with a #raredisease. Learn more: https://t.co/htxGUrdXQ4 #CaregivingHappens #NFCMonth

[Aceragen, Inc @aceragen]

Learn more about the presentation of Farber disease in a Rheumatology clinic at the ACR Convergence 2022 poster session. Visit poster 137, in-person or virtually, on Saturday, November 12th from 1:00 – 3:00 PM EST. #ACR22 #FarberDisease #Aceragen

[Aceragen, Inc @aceragen]

Connect with us on November 3 at the American Cystic Fibrosis Conference! You can learn more about our work developing sodium fusidate, a potential #antibiotic treatment for #cysticfibrosis exacerbations at https://t.co/6z9J6epT4H.
#NACFC #Aceragen

[Aceragen, Inc @aceragen]

Connect with us on November 3 at the American Cystic Fibrosis Conference! You can learn more about our work developing sodium fusidate, a potential #antibiotic treatment for #cysticfibrosis exacerbations at https://t.co/6z9J6epT4H.
#NACFC #Aceragen

[Aceragen, Inc @aceragen]

Today, we announce that @iderapharma has completed its acquisition of @aceragen. With our combined resources, we will move forward together to address rare, orphan pulmonary and rheumatic diseases. Read the full press release at https://t.co/iAd7tFoDGO.

[Aceragen, Inc @aceragen]

Farber disease is an important diagnosis for pediatric rheumatologists to distinguish from JIA. Join Aceragen on Thursday, September 22 at 18:15 at the 28th European Paediatric Rheumatology Congress to learn more! https://t.co/RawarNrxUl
#PReS2022 #FarberDisease #Aceragen

[Aceragen, Inc @aceragen]

Expanding #NewbornScreening requires better methodologies and treatments for #rarediseases. #Aceragen is focused on developing new therapeutic options for those living with rare diseases, including #Farberdisease. Read more at https://t.co/ftaOK5wWIo and https://t.co/ZBcreOZHck.

[Aceragen, Inc @aceragen]

September is Newborn Screening Awareness Month! #NewbornScreening is an essential public health service that allows for early diagnosis and treatment of #rarediseases like cystic fibrosis and lysosomal disorders. Learn more at https://t.co/UFxTkmzsyN and https://t.co/noDQI051lF.

[Aceragen, Inc @aceragen]

Join us today at the #SSIEM Poster Walk. Dr. John Mitchell will present data on patient reported outcomes from the #Farberdisease Natural History Study. Understanding the burden of disease from patients is foundational to development work. Learn more at https://t.co/EZ5ZyNIdbN.

[Aceragen, Inc @aceragen]

Farber disease is a progressive lysosomal storage disorder with profound morbidity and mortality. Meet us tomorrow at #SSIEM 2022 to learn about our work on the clinical development of a potential #Farberdisease treatment. Learn more at https://t.co/noDQI051lF. #Aceragen

[Aceragen, Inc @aceragen]

Aceragen will be at the SSIEM Annual Symposium in Freiburg, Germany. Visit us to learn about our work with ACG-801 as potential Farber disease treatment. Register to attend the in-person event at https://t.co/WbaI7lWs2R.
#SSIEM #FarberDisease #Aceragen

[Aceragen, Inc @aceragen]

Nils Confer has spent his career building Medical Affairs programs and teams that improve patient diagnosis capabilities. Meet Dr. Confer and the rest of the Aceragen team at https://t.co/Ure8XMCMNW.
#Medicine #HealthCare #Aceragen